Microfluidics Intl (fka MFLU)

[daysleeper]

CEO Patrick bought 10,000 shares at 1.34 on the 18th so it's pretty clear from the news that the stockholders are gonna win the $2 pps

[mike306oh]

Got my nice reward today. Only been here for less than a week.

Good luck all!

Mike

[MWM]

It's hard to hold anything as long as most have been here...

With that tiny O/S, we all had visions of much more...

On to the next one!

I'm in love with Great Western Minerals, if anyone is looking for a good Heavy REE mineral play...

GL!

[cfoofme]

I sold half of mine a year or so ago at .90 for a loss. Guess I should have held but you know what they say about hindsight.

[MWM]

I have a friend who I know was still holding on, I'm sure he's a happy camper to a degree...

[cfoofme]

Do we sell now or wait for the offer?

[cfoofme]

Well, after all these years we finally get a bonus,lol.

[MWM]

MFLU (Microfluidics Intl to be acquired by IDEX Corp for $1.35 per share).

[cfoofme]

Q3 Financials:

http://ih.advfn.com/p.php?pid=nmona&article=45249980&symbol=MFLU

[cfoofme]

http://ih.advfn.com/p.php?pid=nmona&article=45158539&symbol=MFLU

[cfoofme]

Microfluidics International Corporation to Report Third Quarter 2010 Financial Results on November 16, 2010
Microfluidics Intl Corp (BB) (OTCBB:MFLU)
Intraday Stock Chart
Today : Tuesday 9 November 2010
Microfluidics International Corporation (OTC Bulletin Board: MFLU) announced today the Company will release third quarter 2010 financial results on Tuesday, November 16, 2010, at 8:30am ET.

[cfoofme]

New MFLU buy rec from from Dawson James Research report.

http://www.dawsonjames.com/portal/MFLU_Initiation_10_18_2010.pdf

[hotpenny]

I have been trying to buy

but orders won't go thru!
Maybe no one wants to sell? lol

[cfoofme]

Sure looks like it-I was expecting a jump in pps this morning.

[hotpenny]

Hmmm Is the market asleep on this?

[cfoofme]

MFLU + 30% revenue Q2 2010 vs Q2 2009:

http://ih.advfn.com/p.php?pid=nmona&article=43949526&symbol=MFLU

[cfoofme]

From RB board and Andre who attended stockholder meeting:

By: andre727
18 Jun 2010, 05:10 PM EDT
Rating: Rate this post: Msg. 466 of 469
(Reply to 464 by andre727)

Jump to msg. #
OK. I just got home, have about 25 minutes before getting ready to head out again, and I'll try my best to at least begin my report on the annual meeting. I may have to pause for a bit to use the Internet to determine information like the correct spelling of people's names, etc.

First of all, in order to set the scene, I thought it would be useful to identify at least some of the people who were there. Of course, the company's officers were there (http://www.microfluidicscorp.com/index.php?option=com_content&view=article&id=41&Itemid=9), as were the directors. Former director Jim Little was there as well in his capacity as shareholder of the company. There were NO (zero) members of the former management team in attendance. Other prominent people present were the respective managers of American and "West Asia" sales Bill Kober...and European and "East Asia" sales Xavier Leroy. Former Asian head of sales Kenneth Chu was there as well (it struck me that he was there as a means by which people could say good-bye to this kindly, older Oriental gentleman).

And both before and after the meeting, I had the opportunity to speak with many of the above...and overheard others' conversations with many of the above.

Some key bits of information in which other investors may have an interest include the following:

"We had a good quarter last quarter and we're having a good quarter this quarter."

"The two new directors bring an extraordinary level of expertise and connctions to the table. If we were to pay them as consultants, it would cost the firm many, many times the relatively small amount of money they'll get as directors".

I'm running out of time but let me make mention of one of my biggest concerns about Microfluidics...and that's the loss of the $2.5 annual revenues in Japan that the company generated in 2004 and 2005 which came to an abrupt halt during the third quarter of 2006.

Powrex in Japan seems like the real deal as a committed partner of the company. I learned that they've already spent $600,000 in promoting the company's products, most notably the MRT but also other company products. While they seem absolutely astonished by the potential of the MRT, they have also already generated orders for the company's Microfluidizer line. I further learned that when there may have been a company "all hands on deck" sales meeting in the past, MAYBE one Mizuho rep would show up. Powrex sends at least 4 people nowadays.

That's GREAT news. If Microfluidics can once again become a player in Japan, that's clearly preferable to having almost no presence in Japan aside from getting approximately $100,000 in spare parts orders from Mizuho each quarter.

I think we're all in agreement that this company needs growth. And I'll discuss that need for growth in my next entry. But Powrex may be one means that the company might ratchet their revenue levels into higher territory.

OK...that's all for now.

I'll have more on the MRT and other topics as well. Stay tuned.

[cfoofme]

21% revenue increase:

http://ih.advfn.com/p.php?pid=nmona&article=42758518&symbol=MFLU

[cfoofme]

Q1 results to be released May 11 @ 8:30 am. Does this mean results are good?



http://ih.advfn.com/p.php?pid=nmona&article=42652101&symbol=MFLU

[cfoofme]

2X average vol today on news.

[cfoofme]

Microfluidics Introduces Revolutionary Bottom-up Technology as a Platform for Continuous Pharmaceutical Manufacturing
High Shear Processing Leader Unveils Controlled, Scalable Approach at INTERPHEX 2010 (April 20-22, NYC)

Newton, MA (PRWEB) April 21, 2010 -- At INTERPHEX 2010 (April 20-22, NYC), Microfluidics International Corporation (OTCBB: MFLU), the gold standard in pharmaceutical nanomaterials processing, will introduce Microfluidics Reaction Technology™ (MRT) as a cutting-edge platform for continuous pharmaceutical manufacturing. Combining a unique high shear fluid processor with expert process development, MRT is a revolutionary technology for bottom-up nanoparticle creation:




According to an independent 2010 survey that we commissioned, 80 percent of pharmaceutical companies plan to invest in continuous crystallization technology

MRT is the technology they are seeking. It has the potential to revolutionize pharmaceutical production by serving as a scalable platform for continuous manufacturing and by enabling pharma companies to make purer, more consistent drugs faster with improved stability and bioavailability.

MRT allows companies to improve bioavailability, target delivery and encapsulate actives more efficiently than any top-down process or traditional crystallization method

Continuous crystallization for production of highly crystalline drug nanoparticles
Multiphase chemical reactions
Nanoencapsulation of actives
Process intensification


MRT enables companies to transform their manufacturing processes from batch to continuous in order to drastically reduce the time and cost of commercial drug production. By creating nanoparticles bottom-up and controlling their growth, MRT allows research teams to create stable and consistent nanoemulsions, for example, at previously unattainable sizes and narrow distributions (e.g. Azithromycin with a z-average particle size of 82 nm).

Microfluidics will describe the technology in greater detail at its press conference on Wednesday, April 21, 8:30 AM, at INTERPHEX 2010, Jacob K. Javits Convention Center in New York City. POWREX Corporation, the exclusive distributor of Microfluidics technology in Japan, will also speak at the press event on bringing MRT to Asia.

“According to an independent 2010 survey that we commissioned, 80 percent of pharmaceutical companies plan to invest in continuous crystallization technology,” said Michael C. Ferrara, President and CEO of Microfluidics. “MRT is the technology they are seeking. It has the potential to revolutionize pharmaceutical production by serving as a scalable platform for continuous manufacturing and by enabling pharma companies to make purer, more consistent drugs faster with improved stability and bioavailability.”

The technology has immediate value in the pharmaceutical, biotechnology and energy industries. Some of the applications ideal for MRT include more effective and tailored drugs, more efficient catalysts for fuel cells, and nanomaterials for batteries, photovoltaics and supercapacitors.

"MRT allows companies to improve bioavailability, target delivery and encapsulate actives more efficiently than any top-down process or traditional crystallization method," said Thomai “Mimi” Panagiotou, PhD., Microfluidics Chief Technology Officer. “Currently, the typical batch crystallization process involves several steps, often in locations across the country, which can take weeks. MRT simplifies the process and has been proven to reduce production time to a matter of hours. Its innovative capabilities for continuous crystallization and chemical reactions have the potential to transform the manufacture of drugs and chemicals by significantly streamlining the steps, timing and cost of consistent, continuous large-scale commercial production.”

To learn more about MRT attend the Microfluidics INTERPHEX press conference, visit the company’s Interphex Booth #2214 or contact Kris Sarajian at ksarajian(at)mfics(dot)com or (+1) 617.969.5452 x233.

ABOUT MICROFLUIDICS
Microfluidics (OTCBB: MFLU) is the exclusive producer of Microfluidizer® high shear fluid processors for uniform particle size reduction, robust cell disruption and bottom-up nanoparticle creation. Used primarily by pharmaceutical, biotechnology, chemical, cosmetic, nutraceutical/food and energy companies to research, develop and improve products with efficient processes, more than 3,000 Microfluidizer processors are installed at customer sites in 50 countries around the world. The innovative Microfluidics Technology Center, located at the company’s headquarters outside Boston, Mass., is staffed by expert engineers with a wide range of nanotechnology and application experience for Proof of Concept and Process Development services.
By producing smaller particle sizes and a more narrow distribution than other technologies, with scaleup from lab to production guaranteed, Microfluidics enables companies to create tiny particles that achieve big results. To learn more, visit www.microfluidicscorp.com.


http://www.prweb.com/releases/nanotechmanufacturing/nanotechnology/prweb3888574.htm

[cfoofme]

New PR:

http://ih.advfn.com/p.php?pid=nmona&article=42007625&symbol=MFLU

[10 bagger]

MFLU..$0.93

Sold out of total position.. The new president seems happy but as a shareholder I wasn't..$0.04 was what I was looking for at a Min.. Held 21410 in position and selling wasn't pretty.. Might look to reenter in the low $0.60's.. GLTA.. hank

[cfoofme]

One of the better reports and promising looking future and pps down????

[10 bagger]

MFLU.. $1.00

NEWTON, Mass., Feb. 23 /PRNewswire/ -- Microfluidics International Corporation (OTC Bulletin Board:MFLU.ob - News), today reported unaudited financial results for the fourth quarter and year-ended December 31, 2009.

Fourth quarter and recent accomplishments:

•Earned net income for the fourth quarter of $80,000
•Achieved $525,000 in earnings before interest, taxes, depreciation and amortization (EBITDA) for the year
•Generated $15.7 million in revenue for year-ended 2009, a 6% increase over 2008
•Generated $4.2 million in revenue for the fourth quarter, a 23% increase over the same period in 2008
•Reported a $362,000 net loss for the year ended 2009, a $3.6 million reduction from a $4.0 Â million loss in 2008
•Achieved our gross margin target of 60% for the year
•Launched Microfluidics Reaction Technology (MRT) and sold 2 beta units in the fourth quarter

"In 2009, despite unfavorable economic conditions, the Company met its most significant goal since I took over as CEO in late 2007 â?? a positive EBITDA for the year," said Michael C. Ferrara, Chief Executive Officer of Microfluidics. "We achieved this by introducing new products, improving quality and delivery, and strengthening our sales coverage and marketing effectiveness. A positive EBITDA is a significant accomplishment and an important indicator of the promise and opportunity that exists with our business, especially in pharmaceuticals, moving forward. In 2010, we intend to continue this momentum and drive additional growth through the introduction of new products and services, an increased focus on business outside of the United States and an ongoing commitment to excellence across both quality and customer service."

Peter F. Byczko, Vice President of Finance and Chief Accounting Officer added, "Early in 2009 we took significant steps to control costs while continuing to invest in programs that drive growth such as new product development. Â These initiatives are yielding tangible results including improved profitability, rising gross margins and overall increased shareholder value. Â We would expect a sustained recovery in our principal markets to support product line demand and contribute to our goal of achieving pre-tax profitability in 2010, a major step on the road to building a stronger company."

Fourth Quarter Financial Results:

Revenues for the three months ended December 31, 2009 were $4.2 million, an increase of $785,000 or 23%, as compared to revenues of $3.5 million for the three months ended December 31, 2008. North American revenues were $2.7 million, an increase of 5% as compared to $2.5 million in the fourth quarter of 2008. Â Foreign sales for the three months ended December 31, 2009 were $1.6 million, an increase of 71% as compared $934,000 for the fourth quarter of 2008. Our gross margin was 62% in the fourth quarter of 2009 versus 49% for the fourth quarter of 2008. Â Net income was $80,000, or $0.01 per share, for the three months ended December 31, 2009 as compared to a net loss of $1.7 million, or $0.17 per share, for the same period in 2008.

EBITDA was $297,000 for the three months ended December 31, 2009 compared with a $1.4 million EBITDA loss for the same period in 2008. EBITDA is a Non-GAAP financial measure. Â A reconciliation of GAAP net income to Non-GAAP EBITDA is provided in the financial tables that accompany this release and is discussed under the section below titled "Non-GAAP Financial Measures."

Year End Financial Results:

Revenues for the year ended December 31, 2009 were $15.7 million, an increase of $800,000, or 6%, as compared to revenues of $14.9 million for the year ended December 31, 2008. Net loss was $362,000, or $0.03 per share, for the year ended December 31, 2009 as compared to $4.0 million net loss, or $0.39 per share, for the same period in 2008. Â Our gross margin for 2009 was 60% versus 51% in 2008.

EBITDA was $525,000 for the year ended December 31, 2009 compared with a $3.5 million EBITDA loss for the same period in 2008. EBITDA is a Non-GAAP financial measure. Â A reconciliation of GAAP net income to Non-GAAP EBITDA is provided in the financial tables that accompany this release and is discussed under the section below titled "Non-GAAP Financial Measures."

Live Webcast:

Microfluidics International Corporation will host a webcast on Tuesday, February 23, 2010 at 8:30 a.m. Eastern Time. Participants are invited to attend the call by visiting http://www.microfluidicscorp.com/ or by dialing 866-804-6929 (within the United States) or 857-350-1675 (outside the United States). The passcode for participants is 46248590.

A replay will be available approximately two hours after the live call through March 2, 2010. To access the replay, dial 888-286-8010 (within the United States) or 617-801-6888 (outside the United States). The passcode for participants is 87532708. A replay will also be posted on the Company's website approximately two hours after the live call and will be available for a period of 30 days.

About Microfluidics International Corporation

Microfluidics International Corporation designs, manufactures and distributes patented and proprietary high performance Microfluidizer® materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics and inkjet ink industries. The Company applies its 20 plus years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available and has provided manufacturing systems for nanoparticle products for more than 15 years.

Microfluidics is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to the Company's equipment customers.

Non-GAAP Financial Measures:

In addition to the results reported in accordance with generally accepted accounting standards (GAAP) within this release, the Company may reference certain information that is considered a non-GAAP financial measure, including EBITDA, which is defined as earnings before interest, taxes, depreciation and amortization, and Adjusted EBITDA, which is defined as earnings before interest, taxes, depreciation, and amortization, excluding non-cash stock compensation expense recognized and severance payments. Management believes these measures are useful and relevant to management for operational planning and decision making purposes, and informative to investors in their analysis of the Company's underlying business and operating performance. Non-GAAP financial measures should not be considered a substitute for any GAAP measures. Additionally, non-GAAP measures as presented by the Company may not be comparable to similarly titled measures reported by other companies. A reconciliation of GAAP to non-GAAP financial information discussed in this release is contained in the attached exhibits.

Safe Harbor for Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You can identify these statements by the fact that they use words such as "anticipate," "believe," "estimate," "expect," "intend," "project," "plan," "outlook," and other words and terms of similar meaning. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from the potential results discussed in the forward-looking statements. Among the factors that could cause actual results and outcomes to differ materially from those contained in such forward-looking statements are the following: our ability to access sufficient working capital, including our new working capital line; our continued compliance with the representations, warranties and covenants under our existing convertible debenture and working capital line; our continued history of losses, which includes net losses in four of the last five fiscal years; the timing and size of customer orders for our products; the adoption, timing and performance of new technology and products developed by us; changes and advances in technology that may make our products obsolete or reduce demand for our products; our ability to protect and maintain the confidentiality of our intellectual property; our ability to retain key employees and our reliance on a new management team; changes in governmental rules and regulations, including health care and those regulating the exportation of goods; and general economic and business conditions, including those adversely effecting the pharmaceutical and biotechnology industries. For a more detailed discussion of risks and uncertainties which could cause actual results to differ from those contained in our forward-looking statements, see Item 1A, "Risk Factors" in of our most recently filed Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 and our other periodic reports filed with the SEC. You should not place undue reliance on our forward-looking statements, which speak only as of the date they are made. We are providing this information as of this date, and we do not undertake to update the information included in this press release, whether as a result of new information, future events or otherwise.

MICROFLUIDICS INTERNATIONAL CORPORATION Condensed Consolidated Balance Sheets (Unaudited - in thousands, except share and per share amounts) December 31, December 31, 2009 2008 ---- ---- ASSETS Current assets: Cash and cash equivalents $2,185 $1,895 Accounts receivable, net of allowance of $44 at both December 31, 2009 and 2008 2,571 2,181 Inventories 2,916 2,723 Prepaid and other current assets 280 320 --- --- Total current assets 7,952 7,119 Property and equipment, net 891 1,121 Other non-current assets 535 480 --- --- Total assets $9,378 $8,720 ====== ====== LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $545 $986 Accrued expenses 1,727 1,233 Customer advances 1,137 436 ----- --- Total current liabilities 3,409 2,655 Long-term liabilities: Convertible debt 4,679 4,625 ----- ----- Total liabilities 8,088 7,280 ----- ----- Stockholders' equity: Common stock; $.01 par value; 30,000,000 and 20,000,000 shares authorized; 10,630,228 and 10,592,228 shares issued; 10,394,782 and 10,356,782 shares outstanding as of December 31, 2009 and 2008, respectively. 106 106 Additional paid-in capital 18,254 18,042 Accumulated deficit (16,401) (16,039) Treasury stock, 235,446 shares, at cost, as of December 31, 2009 and 2008 (669) (669) ---- ----- Total stockholders' equity 1,290 1,440 ----- ----- Total liabilities and stockholders' equity $9,378 $8,720 ====== ======

MICROFLUIDICS INTERNATIONAL CORPORATION Condensed Consolidated Statements of Operations (Unaudited - in thousands, except share and per share amounts) Three Months Ended Twelve Months Ended December 31, December 31, ------------ ------------ 2009 2008 2009 2008 ---- ---- ---- ---- Revenues $4,249 $3,464 $15,739 $14,871 Cost of sales 1,620 1,756 6,299 7,298 ----- ----- ----- ----- Gross profit 2,629 1,708 9,440 7,573 Operating expenses: Research and development 449 485 1,712 2,116 Selling 1,192 1,517 4,315 4,844 General and administrative 799 1,321 3,290 4,495 --- ----- ----- ----- Total operating expenses 2,440 3,323 9,317 11,455 Income (loss) from operations 189 (1,615) 123 (3,882) Interest expense (127) (104) (505) (154) Interest income - 4 2 25 --- --- --- --- Net income (loss) before taxes 62 (1,715) (380) (4,011) Income tax benefit (18) - (18) - --- --- --- --- Net income (loss) $80 $(1,715) $(362) $(4,011) === ======= ===== ======= Net income (loss) per common share: Basic $0.01 $(0.17) $(0.03) $(0.39) Diluted $0.01 $(0.17) $(0.03) $(0.39) Weighted average number of common and common equivalent shares outstanding: Basic 10,389,782 10,349,282 10,380,157 10,296,296 Diluted 10,605,371 10,349,282 10,380,157 10,296,296

MICROFLUIDICS INTERNATIONAL CORPORATION U.S. GAAP to Non-GAAP Measure Reconciliations Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) (Unaudited - in thousands) Three Months Ended Twelve Months Ended December 31, December 31, 2009 2008 2009 2008 ---- ---- ---- ---- Net income (loss) $80 $(1,715) $(362) $(4,011) Net interest expense 127 100 503 129 Depreciation and amortization 108 229 402 403 Income tax benefit (18) - (18) - --- --- --- --- EBITDA (Non- GAAP Measure) 297 (1,386) 525 (3,479) Severance - 181 415 345 Non-cash compensation 56 62 200 233 --- --- --- --- Adjusted EBITDA $353 $(1,143) $1,140 $(2,901) ==== ======= ====== =======

[cfoofme]

Yes, that was me with a "2" added on end. Sorry for confusion. Thanks much.

Watch this one for a bump up (hopefully) tomorrow after the pre marked Q report.

[Zardiw]

Check your mailbox Stockbuilder.........et z

[cfoofme]

I am expecting a good report considering the upward moving share price over past few weeks (results leaking out,imo).

I was up bigtime a couple of years ago and held expecting much better results then the economy began its downslide. This is a very good co with good mgt. and a great product.

[10 bagger]

MFLU.. $1.05

I rarely look at MFLU because it seems to be a well run company.. I did some work on it the last Qtr. and my estimates were for a $0.062 Qtr..making a huge turn around for the year.. MFLU has moved up it's announcement date and that is good news and could add $0.01 to my EST.. But I would not count on it.. I'm long at present 16410 shares and have sell orders in at $1.08 and 1.12 which I will remove before I release this post.. In fact i'll bump the bid for a few..

02/17/10 2:39 PM EST Buy 2500 MFLU Executed @ $1.07 Details | Edit
02/17/10 2:39 PM EST Buy 2500 MFLU Executed @ $1.07 Details | Edit

hank

[nsomniyak]

do you have a target for MFLU?

[10 bagger]

MFLU.. $1.05

I cover MFLU also on my trading board..

Microfluidics International Corporation to Report Fourth Quarter and Year-end 2009 Financial Results on February 23, 2010

PR Newswire - Feb 17 at 09:36 NONE

Company Symbols: NASDAQ-OTCBB:MFLU

CONFERENCE CALL/AUDIO WEBCAST TO FOLLOW


NEWTON, Mass., Feb. 17 /PRNewswire-FirstCall/ -- Microfluidics International Corporation (OTC Bulletin Board: MFLU) announced today the Company will release fourth quarter and year-end 2009 financial results on Tuesday, February 23, 2010, at 8:30am ET.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090811/NE59652LOGO )

Michael C. Ferrara, President and Chief Executive Officer, and Peter F. Byczko, Vice President of Finance and Chief Accounting Officer, will host a conference call and live audio webcast.

Participants are invited to attend the call by visiting www.microfluidicscorp.com/investors and clicking on the webcast link, or by dialing 866.804.6929 (within the United States) or +1 857.350.1675 (outside the United States). The passcode is 46248590.

A replay will be available beginning approximately two hours after the live call through March 2, 2010. To access the replay, dial 888-286-8010 (within the United States) or 617-801-6888 (outside the United States). The passcode is 87532708. A replay will also be posted on the Company's website approximately two hours after the live call and will be available for a period of two weeks.

SAFE HARBOR FOR FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You can identify these statements by the fact that they use words such as "anticipate," "believe," "estimate," "expect," "intend," "project," "plan," "outlook," and other words and terms of similar meaning. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from the potential results discussed in the forward-looking statements. Among the factors that could cause actual results and outcomes to differ materially from those contained in such forward-looking statements are the following: our ability to access sufficient working capital, including a new working capital line; our continued compliance with the representations, warranties and covenants under our existing convertible debenture; our continued history of losses, which includes net losses in three of the last five fiscal years; the timing and size of customer orders for our products; the adoption, timing and performance of new technology and products developed by us; changes and advances in technology that may make our products obsolete or reduce demand for our products; our ability to protect and maintain the confidentiality of our Intellectual property; our ability to retain key employees and our reliance on a new management team; changes in governmental rules and regulations, including those regulating the exportation of goods; and general economic and business conditions and the financial crisis, including those adversely effecting the pharmaceutical and biotechnology industries. For a more detailed discussion of risks and uncertainties which could cause actual results to differ from those contained in our forward-looking statements, see Item 1A, "Risk Factors" in our annual report on Form 10-K or our most recently filed Quarterly Report on Form 10-Q for the quarter ended September 30, 2009 and our other periodic reports filed with the SEC. You should not place undue reliance on our forward-looking statements, which speak only as of the date they are made. We are providing this information as of this date, and we do not undertake to update the information included in this presentation, whether as a result of new information, future events or otherwise.

ABOUT MICROFLUIDICS

Microfluidics (OTC Bulletin Board: MFLU) is the exclusive producer of Microfluidizer® high shear fluid processors for uniform particle size reduction, robust cell disruption and bottom-up nanoparticle creation. Used primarily by pharmaceutical, biotechnology, chemical, cosmetic, nutraceutical/food and energy companies to research, develop and improve products with efficient processes, more than 3,000 Microfluidizer processors are installed at customer sites in 50 countries around the world. The innovative Microfluidics Technology Center, located at the company's headquarters outside Boston, Mass., is staffed by expert engineers with a wide range of nanotechnology and application experience for Proof of Concept and Process Development services.

By producing smaller particle sizes and a more narrow distribution than other technologies, with scaleup from lab to production guaranteed, Microfluidics enables companies to create tiny particles that achieve big results. To learn more, visit www.microfluidicscorp.com.

SOURCE Microfluidics International Corporation

[MoneyMan]

I like this one. Will be watching for the 4th numbers. If they look good, the future here seems really positive.

2 straight quarters of net income and postitive cash flows goes a long way for a company this size.

[cfoofme]

His thoughts after thinking about the conversation with Mike:



By: Baton
22 Dec 2009, 01:18 PM EST
Rating: Rate this post: Msg. 336 of 336

Jump to msg. #
My Impressions:
After talking to Mike yesterday, I've been thinking about the company and the direction it is going.
Mike has basically done everything he said he would since coming on board. He probably did not know the poor shape the company was in until he had been here a few months, nor did he anticipate the severity of the economic downturn. He has made several difficult decisions regarding staff and now has his people & plan in place.
I expect him to execute as planned. My prediction (barring a plunge back into recession)is that it will be a very good year. I expect him to get several small fund managers interested in our company. Other areas besides pharma should also begin to grow. The reinvestment in international sales should begin to pay-off. I expect earnings to grow and quarterly profits to increase. It won't be that hard to get the stock price up to around $2.50 or higher if the company performs.
Getting the stock listed will be a big challenge, but it is doable at some point.
I've been patient and will continue. I expect that patience to start some payback by mid-year.

[cfoofme]

Well at least we have some news from a poster at another board. It sounds positive to me esp during this down cycle.

By: Baton
22 Dec 2009, 11:04 AM EST
Rating: Rate this post: Msg. 334 of 336

Jump to msg. #
Conversation

OK – I spoke with Mike yesterday. I had called him early in the day and he did not call back until late that afternoon. It was after 7PM EST and you could tell that it had been a long day and he was tired. Kudos for taking the time to return my call. I made it clear that I might be repeating his answers and made sure it was OK to repeat before we started. Since I had spoken to him several times before, I reminded him that I have been a shareholder for over 5 years and that I had a substantial holding.
My big concern is getting the stock moving – both in price and volume. I explained that I would be willing to buy more, but only when I felt that I could sell it when needed without killing the price due to lack of volume. As Mike had stated in the last CC, his plan is to get the company profitable and then hit the street to get investors. He plans on starting in January. I did not ask for details. I told him I thought he needed to give shareholders a reason to continue to hold and be excited.
Some of the specific questions you guys had asked:
MRT – Still early, sold two, profit margins good, price going up.
BOD – He has 10 good candidates. Stock purchase from members not important to him. He wants intelligent members with no buddies in company.
EBITDA profitable this year? Yes
OTHER Profitable area: Pharma is still 80% - seeing some new business from University and energy area.
ASIA – Right people are there, will take time. Recent visit from major company who sent 9 people and spent two weeks.
SWINE Flu – Vaccines remain hot. Mentioned GSK and Novartis as customers.
Q4 Progress. He would not say, but referred me to the backlog numbers from the last CC.
GENERAL Economic climate – His words “We are there” indicating that he thought the company was back and making normal progress.

Other comments:
Mike reiterated that the key is performing Q after Q. He says they are putting a big push on services and that pricing and margins are going up. He said the problem is that the company is just too small. He indicated that we need to grow and that he actually had some acquisitions in mind to help with that. I asked him if the past talk to get on a national listing was just a pipe dream and he said definitely not, that we could go through the ASE to the NAS in time. He ended by saying he was more optimistic than ever and that we had the right people and good leadership. I thanked him for taking the time late in the day during a holiday week.

[cfoofme]

MFLU has profitable 3rd quarter:

Third quarter accomplishments: -- Earned net income for the third quarter of $425,000 -- Achieved $650,000 in earnings before interest, taxes, depreciation and amortization (EBITDA) -- Delivered strong bookings in the third quarter of $4.8 million and a backlog of $4.75 million as of September 30, 2009

-- Generated $4.5 million in revenue for the third quarter, a 27% increase over the same period in 2008


"I am pleased to report that the strategic plan we implemented a year ago has led us to our first profitable quarter since my joining the Company," said Michael C. Ferrara, Chief Executive Officer of Microfluidics. "We will continue to innovate with new products, increase international representative and distributor coverage, streamline costs and improve quality in support of our customers as we strive to carry this positive momentum through the second half of the year and into 2010."



http://ih.advfn.com/p.php?pid=nmona&cb=1257200298&article=40168990&symbol=NB%5EMFLU

[cfoofme]

Microfluidics International Corporation to Report Third Quarter 2009 Financial Results on November 2, 2009




- Conference Call/Audio Webcast to Follow -

NEWTON, Mass., Oct. 27 /PRNewswire/ -- Microfluidics International Corporation (OTC:MFLU) (BULLETIN BOARD: MFLU) announced today that the Company will release third quarter 2009 financial results on Monday, November 2, 2009, after the closing of the U.S. financial markets.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090811/NE59652LOGO )

Michael C. Ferrara, President and Chief Executive Officer, and Peter F. Byczko, Vice President of Finance and Chief Accounting Officer, will host a conference call and live audio webcast at 4:30 PM Eastern Time on Monday, November 2, 2009.

Participants are invited to attend the call by visiting http://www.microfluidicscorp.com/investors and clicking on the Thomson Reuters webcast link, or by dialing 866-356-4281 (within the United States) or [phone] (outside the United States). The passcode for participants is 96732749.

A replay will be available approximately two hours after the live call through November 9, 2009. To access the replay, dial 888-286-8010 (within the United States) or 617-801-6888 (outside the United States). The passcode for participants is 69691770. A replay will also be posted on the Company's website approximately two hours after the live call and will be available for a period of 30 days.

[cfoofme]

Post from another board:

By: sixersadvantcom
11 Aug 2009, 08:55 PM EDT
Rating: Rate this post: Msg. 266 of 267

Jump to msg. #
Second Quarter Results.

1.Gross Margin 56.6%, Great.

2.Operating Expenses Down 31%, Great.

3.Revenue $3.47 million, Room for improvement but the increase of backlog to $4.3 million is the spoonful of sugar which helps the medicine go down.

4.Positive EBITDA good but looking for positive earnings.

5.Overall very good especially considering the economic climate.

bob

[cfoofme]

Second quarter financials:

http://ih.advfn.com/p.php?pid=nmona&cb=1250019362&article=38995510&symbol=NB%5EMFLU

[cfoofme]

Whats up with the huge pps increase today with no news out? Something must be coming.

[cfoofme]

Anyone want to be co-mod here? If so, I will add you as I am not the most computer literate person around. I was able to update the ibox somewhat without screwing it up,lol.

[cfoofme]

Good summation from a poster on another board:

By: andre727
05 Jun 2009, 01:09 PM EDT
Rating: Rate this post: Msg. 238 of 246
(Reply to 237 by andre727)

Jump to msg. #
Annual meeting

As many of you know, an annual meeting has as its primary purpose the tabulation of votes and is the very first part of the meeting. ALL items that had to be voted upon were PASSED. So our board of directors was elected without exception, our auditors were approved, and it has been authorized that our outstanding shares could go to 30 million shares when it previously could not have gone higher than 20 million shares. Chairman of the Board James Little presided over this section of the meeting.

Then, we heard Mike Ferrara give a slide presentation on the company. Of greatest interest to me was to hear him reiterate, as of June 4, that he felt that it was a reasonable expectation that MFLU would be EBITDA positive this year. Given that I think he’s less inclined to BS along the lines of Irwin Gruverman (remember Gruverman’s “investors will be pleased when we release this quarter’s information”…only to ultimately find out that the quarter was one in which the company had a net loss?), and that he must know how THIS quarter is going as of June 4, I thought that was a fairly significant statement , particularly after a Q1 $400,000 plus loss (albeit largely due to “severance payments”).

Another interesting slide was one in which he labeled 2008, 2009, and 2010 with descriptive words. 2008 was “fix”, a process that apparently is still ongoing. Apparently, the company’s headquarters infrastructure was/is being fixed, its machines were/are being fixed, and its strategy and direction were and still are being fixed. But “fixing” the company was the main theme of 2008.

2009 is “lean” referring to the company “leaning” towards profitability in 2009.

And 2010 is “grow”.

Let me just say a few words about “fix”. We know about management changes, the correction of problems with the machines, the change in corporate culture, strategy, and direction. But you really have to actually visit the company to fully appreciate how comprehensively the company’s infrastructure has changed.

It’s not just the completely renovated offices, lunch room, small meeting rooms with telephones to be used by visiting clients. I had been taken back into the assembly area by Jack Swig from time to time in the past and was very unimpressed by the drab, dingy, disorganized, poorly lighted assembly area. Production equipment worth hundreds of thousands of dollars, perhaps to be ultimately installed in pharmaceutical clean rooms, looked like they were being installed in some crusty, oldtimer automotive garage (Chief Engineer Bill Conroy told me that his daughter had said that it looked like a basement). Maybe MFIC didn’t have too many client visits but, if they did, they couldn’t help but be concerned about the company’s professionalism after seeing that assembly area.

Yesterday, I was taken back by Bill Conroy and was amazed to see a spotlessly clean, very well lit, completely organized assembly area with shiny clean floors, sectioned off by whatever machine would be built in that section. Any client that were to visit MFLU now would be undoubtedly impressed. The perception of extraordinary professionalism will of course not only result in more sales, but perhaps greater profit margin sales. When you go to a hole in the wall restaurant, you expect to pay “cheap eats” prices no matter how good the food may be. And vice versa when you’re amazed by the “luxury” of the restaurant.

Here’s some tidbits that I think may be of interest. Of course, no one discussed, even in private conversations, how this quarter’s going. However, I can assure you that everyone was in a confident, jovial mood, completely unlike what you might expect if the company were going down the tubes or facing a liquidity crisis.

I perked up when I heard Mike Ferrara mention in his presentation that “swine flu” is (present tense) “helping us out“. Apparently, “people are scared”. If that means what I think that means then I believe that the company might have received some windfall “swine flu vaccine” order or orders of some note. And most likely vaccine equipment will be production equipment and not necessarily basic research lab equipment. Just my interpretation and opinion for you to mull over as I did. Of course, I could be completely wrong.

Nice to think that MFLU is a swine flu play.

When I was talking to new comptroller Peter Byczko, I mentioned in the context of the conversation that investors who had been with the company for a while have suffered. His spontaneous response, and I don’t remember his exact words, was that “it’s a good thing we’re coming back” (or at least that's the message that I think I got).

Again, positivity just oozed out of everybody. Just reading between the lines, things look good.

As for the MRT, apparently they’ve had things breaking in a positive way on that front. I don’t know what that will mean in terms of revenue numbers but CTO Mimi was bubbling with enthusiasm about how well things were going. As someone who’s looked on in amazement at the company’s ZERO sales (!!!???) since first hearing in 2004 that the MMR (the forerunner of the MRT) was selected by the MIT Emerging Technologies Showcase as a “technology poised to make a significant impact upon the world”, it’s about damn time!

[di4]

Microfluidics Expands Distributorship in Japan with Exclusive POWREX Partnership to Meet Increased Demand in Pharmaceutical, Biotechnology and Energy Industries
Jun 3, 2009 8:15:00 AM


Email Story Discuss on ZenoBank

View Additional ProfilesNEWTON, Mass., June 3 /PRNewswire-FirstCall/ -- Microfluidics, a wholly owned subsidiary of Microfluidics International Corporation (OTC Bulletin Board: MFLU), and POWREX Corporation have entered into an exclusive distributorship agreement whereby POWREX will market, sell and service Microfluidizer(R) high shear fluid processors in the pharmaceutical, biotechnology and energy industries throughout Japan.


Japan is the second-largest individual country pharmaceutical market in the world, and is a clear leader in innovative energy technologies, including fuel cells and photovoltaics. With this agreement, POWREX customers throughout Japan will be able to take wider advantage of the unique benefits provided by Microfluidizer high shear fluid processors to improve quality and efficiency in the lab as well as production.


POWREX will distribute the entire line of Microfluidizer top-down processors, which represents the widest range of pharmaceutical processors available, as well as novel Microfluidics Reaction Technology (MRT) for bottom-up creation of nanoparticles and efficient nanoencapsulation via continuous crystallization and chemical reactions.


"Microfluidics is honored to partner with such a respected corporation as POWREX," said Michael C. Ferrara, Microfluidics Chief Executive Officer. "We believe Microfluidizer processors are the undisputed gold standard in the biopharma industry, and MRT represents a tremendous opportunity particularly for energy researchers. We believe POWREX is well positioned to bring these technologies to a market eager for solutions."


Established in 1950 as Fuji Kikai Kohgyo Co, Ltd., and based in Hyogo, POWREX has grown over the past half-century to become one of the largest processing technologies companies in Japan. POWREX partners with its customers to deliver value-added original powder processing solutions including hardware, software and engineering services. By supplementing these core offerings with Microfluidics technology, POWREX will provide a more complete suite of best-in-class processors and scientific expertise to support customers' demanding research requirements.


Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You can identify these statements by the fact that they use words such as "anticipate," "believe," "estimate," "expect," "intend," "project," "plan," "outlook," and other words and terms of similar meaning. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from the potential results discussed in the forward-looking statements. Among the factors that could cause actual results and outcomes to differ materially from those contained in such forward-looking statements are the following: our ability to access sufficient working capital, including a new working capital line; our continued compliance with the representations, warranties and covenants under our existing convertible debenture; our continued history of losses, which includes net losses in three of the last five fiscal years; the timing and size of customer orders for our products; the adoption, timing and performance of new technology and products developed by us; changes and advances in technology that may make our products obsolete or reduce demand for our products; our ability to protect and maintain the confidentiality of our intellectual property; our ability to retain key employees and our reliance on a new management team; changes in governmental rules and regulations, including those regulating the exportation of goods; and general economic and business conditions and the financial crisis, including those adversely effecting the pharmaceutical and biotechnology industries. For a more detailed discussion of risks and uncertainties which could cause actual results to differ from those contained in our forward-looking statements, see Item 1A, "Risk Factors" of our most recently filed Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and our other periodic reports filed with the SEC. You should not place undue reliance on our forward-looking statements, which speak only as of the date they are made. We are providing this information as of this date, and we do not undertake to update the information included in this press release, whether as a result of new information, future events or otherwise.


About Microfluidics

Microfluidics, a wholly owned subsidiary of Microfluidics International Corporation, is a supplier of advanced fluid processing equipment and reaction technology for laboratory, pilot scale and manufacturing applications. Microfluidics is a leader in innovative technology and comprehensive solutions for formulations requiring repeatability and for the production of uniformly distributed nanoparticles.

Microfluidics has been a worldwide supplier of Microfluidizer(R) high shear fluid processing systems to the biotechnology, pharmaceutical, chemical and cosmetics industries since 1984. As a leader in the field, Microfluidics has enabled numerous companies and institutions to formulate, validate and produce licensed drugs for the worldwide healthcare market.

Companies seeking to produce difficult-to-formulate products or to find better methods of bio-processing can take advantage of complimentary sample testing at any of three Microfluidics facilities. Visit www.microfluidicscorp.com, email [e-mail] or contact Microfluidics at 800.370.5452 for application information.


SOURCE Microfluidics International Corporation



----------------------------------------------
Kris Sarajian of Microfluidics International Corporation
[phone]
ext 233
[e-mail]

[di4]

Microfluidics International Corporation Announces First Quarter 2009 Financial Results
May 12, 2009 8:03:00 AM
Copyright Business Wire 2009


Email Story Discuss on ZenoBank

View Additional ProfilesNEWTON, Mass.--(BUSINESS WIRE)-- Microfluidics International Corporation (OTCBB: MFLU) today reported unaudited financial highlights for the first quarter ended March 31, 2009.

First Quarter Accomplishments

-- Maintained revenues from the prior year's quarter despite global
economic downturn
-- Reduced corporate cost-structure during the quarter to 2007 levels under
the direction of the new leadership team

"Microfluidics had a solid first quarter and we are pleased to report that we are beginning to see increased demand for our products and services in our core growth market--pharmaceuticals," said Michael C. Ferrara, Chief Executive Officer and President of Microfluidics. "The positive signs we saw in our first quarter revenues combined with our recent cost-containment measures have us on track to achieve our goal of obtaining positive EBITDA for the year 2009--a major milestone for the Company."

First Quarter Financial Results

Revenues for the three months ended March 31, 2009 were $3,559,000, an increase of $37,000, or 1.1%, as compared to revenues of $3,522,000 for the three months ended March 31, 2008. North American revenues increased by 64% and services revenues increased by approximately 50% in comparison to the first quarter of 2008, offsetting a 44.8% decline in foreign sales. The Company believes the decline in foreign sales is a result of pricing pressure in Asia Pacific and the effects of the global economic downturn.

Net loss, as measured under U.S. generally accepted accounting principles ("GAAP"), was $690,000, or $0.07 per diluted share, for the three months ended March 31, 2009 as compared to $445,000 net loss, or $0.04 per diluted share, for the same period in 2008.

EBITDA loss was $469,000, or $0.05 per diluted share, for the three months ended March 31, 2009 compared with a $410,000 EBITDA loss, or $0.04 per diluted share, for the same period in 2008.

Live Webcast

Microfluidics International Corporation will host a webcast on Tuesday, May 12, 2009 at 8:30 a.m. Eastern Time. Participants are invited to attend the call by visiting www.mficcorp.com and clicking on the webcast link in the Investors, Events section or by dialing 800-638-4817 (within the United States) or 617-614-3943 (outside the United States). The passcode for participants is 25898820.

A replay will be available approximately two hours after the live call through May 19, 2009. To access the replay, dial 888-286-8010 (within the United States) or 617-801-6888 (outside the United States). The passcode for participants is 89775077. A replay will also be posted on the Company's website approximately two hours after the live call and will be available for a period of 30 days.

About Microfluidics International Corporation

Microfluidics International Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer(R) materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics and inkjet ink industries. Microfluidics International Corporation applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available and has provided manufacturing systems for nanoparticle products for more than 15 years.

The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to Microfluidics International Corporation equipment customers.

Safe Harbor for Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You can identify these statements by the fact that they use words such as "anticipate," "believe," "estimate," "expect," "intend," "project," "plan," "outlook," and other words and terms of similar meaning. These statements involve a number of risks and uncertainties that could cause actual results to differ materially from the potential results discussed in the forward-looking statements. Among the factors that could cause actual results and outcomes to differ materially from those contained in such forward-looking statements are the following: our ability to access sufficient working capital, including a new working capital line; our continued compliance with the representations, warranties and covenants under our existing convertible debenture; our continued history of losses, which includes net losses in three of the last five fiscal years; the timing and size of customer orders for our products; the adoption, timing and performance of new technology and products developed by us; changes and advances in technology that may make our products obsolete or reduce demand for our products; our ability to protect and maintain the confidentiality of our intellectual property; our ability to retain key employees and our reliance on a new management team; changes in governmental rules and regulations, including those regulating the exportation of goods; and general economic and business conditions and the financial crisis, including those adversely effecting the pharmaceutical and biotechnology industries. For a more detailed discussion of risks and uncertainties which could cause actual results to differ from those contained in our forward-looking statements, see Item 1A, "Risk Factors" of our most recently filed Annual Report on Form 10-K for the fiscal year ended December 31, 2008 and our other periodic reports filed with the SEC. You should not place undue reliance on our forward-looking statements, which speak only as of the date they are made. We are providing this information as of this date, and we do not undertake to update the information included in this press release, whether as a result of new information, future events or otherwise.

EBITDA and Non-GAAP Measures

In addition to the results reported in accordance with generally accepted accounting standards (GAAP) within this release, the Company may reference certain information that is considered a non-GAAP financial measure. Management believes these measures are useful and relevant to management and investors in their analysis of the Company's underlying business and operating performance. Management also uses this information for operational planning and decision-making purposes. Non-GAAP financial measures should not be considered a substitute for any GAAP measures. Additionally, non-GAAP measures as presented by the Company may not be comparable to similarly titled measures reported by other companies. One specific non-GAAP measure used by the Company is "EBITDA", which is defined as earnings before interest, taxes, depreciation and amortization. Management utilizes the line item non-GAAP operations statement for operational planning and decision-making purposes. A reconciliation of GAAP to non-GAAP financial information discussed in this release is contained in the attached exhibits.


MICROFLUIDICS INTERNATIONAL CORPORATION

Condensed Consolidated Balance Sheets

(Unaudited - in thousands, except share and per share amounts)

March 31, December 31,

2009 2008

ASSETS

Current assets:

Cash and cash equivalents $ 850 $ 1,895

Accounts receivable, net of allowance of $44 both
at 2,536 2,181
March 31, 2009 and December 31, 2008, respectively

Inventories 2,737 2,723

Prepaid and other current assets 220 320

Total current assets 6,343 7,119

Property and equipment, net 1,109 1,121

Other non-current assets 481 480

Total assets $ 7,933 $ 8,720

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable $ 1,084 $ 986

Accrued expenses 1,151 1,233

Customer advances 280 436

Total current liabilities 2,515 2,655

Long-term liabilities:

Convertible debt 4,638 4,625

Total liabilities 7,153 7,280

Stockholders' equity:

Common stock; $.01 par value; 20,000,000 shares
authorized;
10,607,228 and 10,592,228 shares issued;
10,371,782 and 106 106
10,356,782 shares outstanding as of March 31, 2009
and
December 31, 2008, respectively

Additional paid-in capital 18,072 18,042

Accumulated deficit (16,729 ) (16,039 )

Treasury stock, 235,446 shares, at cost, as of
March 31, 2009 and (669 ) (669 )
December 31, 2008

Total stockholders' equity 780 1,440

Total liabilities and stockholders' equity $ 7,933 $ 8,720




MICROFLUIDICS INTERNATIONAL CORPORATION

Condensed Consolidated Statements of Operations

(Unaudited - in thousands, except share and per share amounts)

For The Three Months Ended

March 31,

2009 2008

Revenues $ 3,559 $ 3,522

Cost of sales 1,653 1,609

Gross profit 1,906 1,913

Operating expenses:

Research and development 452 491

Selling 1,216 932

General and administrative 804 941

Total operating expenses 2,472 2,364

Loss from operations (566 ) (451 )

Interest expense (126 ) (5 )

Interest income 2 11

Net loss $ (690 ) $ (445 )

Net loss per common share:

Basic $ (0.07 ) $ (0.04 )

Diluted $ (0.07 ) $ (0.04 )

Weighted average number of common and common
equivalent shares outstanding:

Basic 10,370,628 10,260,482

Diluted 10,370,628 10,260,482




MICROFLUIDICS INTERNATIONAL CORPORATION

U.S. GAAP to Non-GAAP Measure Reconciliations and

Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA)

(Unaudited - in thousands, except share and per share amounts)

For The Three Months Ended

March 31,

2009 2008

Net loss $ (690 ) $ (445 )

Net interest expense (income) 125 (6 )

Depreciation and amortization 96 41

EBITDA (Non-GAAP Measure) $ (469 ) $ (410 )

Weighted average number of

common and common equivalent

shares outstanding:

Basic: 10,370,628 10,260,482

Diluted: 10,370,628 10,260,482

EBITDA per common share

(Non-GAAP Measure):

Basic: $ (0.05 ) $ (0.04 )

Diluted: $ (0.05 ) $ (0.04 )






Source: Microfluidics International Corporation


----------------------------------------------
MacDougall Biomedical Communications
Sarah Cavanaugh
781-235-3060
[e-mail]
or
Microfluidics International Corporation
Peter F. Byczko
617-969-5452
Vice President of Finance and Chief Accounting Officer
[e-mail]

[di4]

Microfluidics International Corporation to Report First Quarter 2009 Results on May 12, 2009
Conference Call/Audio Webcast to Follow
May 8, 2009 8:03:00 AM
Copyright Business Wire 2009


Email Story Discuss on ZenoBank

View Additional ProfilesNEWTON, Mass.--(BUSINESS WIRE)-- Microfluidics International Corporation (OTCBB: MFLU) announced today that the Company will release first quarter 2009 financial results on Tuesday, May 12, 2009, before the opening of the U.S. financial markets.

Michael C. Ferrara, President and Chief Executive Officer, and Peter F. Byczko, Vice President of Finance and Chief Accounting Officer, will host a conference call and live audio webcast at 8:30 AM Eastern Time on Tuesday, May 12, 2009.

Participants are invited to attend the call by visiting www.mficcorp.com and clicking on the webcast link in the Investors, Events section or by dialing 800.638.4817 (within the United States) or 617.614.3943 (outside the United States). The passcode for participants is 25898820.

A replay will be available approximately two hours after the live call through May 19, 2009. To access the replay, dial 888-286-8010 (within the United States) or 617-801-6888 (outside the United States). The passcode for participants is 89775077. A replay will also be posted on the Company's website approximately two hours after the live call and will be available for a period of 30 days.

To register for this call, click here.

About Microfluidics International Corporation

Microfluidics International Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer(R) materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics and ink jet ink industries. Microfluidics International Corporation applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available, and has provided manufacturing systems for nanoparticle products for more than 15 years.

The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to Microfluidics International Corporation equipment customers.





Source: Microfluidics International Corporation


----------------------------------------------
MacDougall Biomedical Communications
Sarah Cavanaugh
781-235-3060
[e-mail]

[cfoofme]

Microfluidics International Corporation Announces Fourth Quarter and Year-end 2008 Financial Results
8:00a ET March 30, 2009 (Business Wire)
Microfluidics International Corporation (OTCBB: MFLU) today reported financial results for the quarter and year-ended December 31, 2008.

2008 Accomplishments:

-- Attracted a new, committed leadership team with impressive experience in global sales, service, operations and marketing to build a company culture driven by the customer and accountability

-- Developed and began to implement a three-year strategic plan which for the first time in the Company's history quantifies served markets and, ultimately, establishes pharmaceutical growth as the driving priority

-- Reinvented global sales, significantly improving existing coverage and adding dedicated coverage in North America, EMEA and Asia Pacific--all important steps in establishing Microfluidics as a truly global company

-- Introduced formal marketing programs, resulting in a doubling of qualified leads in core vertical segments, and broadened our services offerings

-- Laid out a technology plan for the future of the Company by implementing a formal process for new product and technology development

-- Upgraded manufacturing and customer facilities and significantly improved quality across the corporation

-- Successfully financed the Company to meet our short-term needs and support our near-term growth plans

"2008 was a year of transition and, most importantly, a transformational year for Microfluidics," said Michael C. Ferrara, Chief Executive Officer and President of Microfluidics. "The Company made a number of wise and long overdue investments in people, quality and facilities fundamental to building a foundation for sustainable, profitable growth and critical to our ability to compete globally. These investments were mostly non-recurring, but along with the challenging macro-economic environment led to a significant loss for the year. However, I firmly believe that the Company has been fundamentally restructured to effectively compete, achieve sustainable profitability and maintain adequate cash reserves, which should result in significantly improved shareholder value in 2009 and beyond."

For the quarter ended December 31, 2008, the Company reported revenues of $3.5 million and an EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) loss of $1.4 million or $0.13 per share, as compared with $4.3 million in revenues and EBITDA of $287,000 or $0.03 per share in 2007. Net loss for the fourth quarter ended December 31, 2008 was $1.7 million or $0.17 per share compared with a net loss of $124,000 or $0.02 per share in 2007.

For the year ended December 31, 2008, the Company reported revenues of $14.9 million and an EBITDA loss of $3.5 million or $0.34 per share as compared with $13.0 million in revenues and an EBITDA loss of $1.0 million or $0.10 per share in 2007. Net loss for the twelve-month period ended December 31, 2008 was $4.0 million or $0.39 per share compared with a net loss of $1.5 million or $0.15 per share in 2007.

"As a direct result of our 2008 financials and the current global economic crisis, we took a number of steps in the first quarter of 2009 to address our cost structure as we moved into this new year, putting us on the path to EBITDA profitability," continued Ferrara. "We've reduced headcount by approximately 17%, cut expenses significantly and reengineered internal processes to improve efficiency and output. In total, our 2009 operating expense plans are under our 2007 actual spending levels and we will be continually vigilant in minimizing our expenses and our cost structure as this global economy plays out through the year

[cfoofme]

Microfluidics International Corporation to Report Fourth Quarter and 2008 Year-end Financial Results on March 30, 2009
4:03p ET March 23, 2009 (Business Wire)
Microfluidics International Corporation (OTCBB: MFLU) announced today that the Company will release fourth quarter and 2008 year-end financial results on Monday, March 30, 2009, before the opening of the U.S. financial markets.

Michael C. Ferrara, President and Chief Executive Officer, will host a conference call and live audio webcast at 8:30 AM Eastern Time on Monday, March 30, 2009.

Participants are invited to attend the call by visiting www.mficcorp.com and clicking on the webcast link in the Investors, Events section or by dialing 800-884-5695 (within the United States) or 617-786-2960 (outside the United States). The passcode for participants is 53493380.

A replay will be available approximately two hours after the live call through April 6, 2009. To access the replay, dial 888-286-8010 (within the United States) or 617-801-6888 (outside the United States). The passcode for participants is 70592092. A replay will also be posted on the Company's website approximately two hours after the live call and will be available for a period of 30 days.

About Microfluidics International Corporation

Microfluidics International Corporation, through its Microfluidics Division, designs, manufactures and distributes patented and proprietary high performance Microfluidizer(R) materials processing and formulation equipment to the biotechnology, pharmaceutical, chemical, cosmetics and ink jet ink industries. Microfluidics International Corporation applies its 20 years of high pressure processing experience to produce the most uniform and smallest liquid and suspended solid particles available, and has provided manufacturing systems for nanoparticle products for more than 15 years.

The Company is a leader in advanced materials processing equipment for laboratory, pilot scale and manufacturing applications, offering innovative technology and comprehensive solutions for nanoparticles and other materials processing and production. More than 3,000 systems are in use and afford significant competitive and economic advantages to Microfluidics International Corporation equipment customers.

SOURCE: Microfluidics International Corporation

[cfoofme]

Microfluidics Unveils New Biopharma Series of Processors at INTERPHEX 2009
Portable Aseptic, Enhanced and Basic models ideal for lab, clinical trial and small batch settings

Newton, Mass. - March 17, 2009 - Today at the INTERPHEX 2009 conference and trade show in New York, NY, Microfluidics unveiled an exciting new line of M-110EH-30 series processors specially engineered for the biopharmaceutical industry. Available in portable Aseptic, Enhanced and Basic models, these high shear fluid processors operate at pressures up to 30,000 psi and are ideal for lab research, clinical trials and small volume production needs.

Over 1,100 pharmaceutical companies - including 17 of the top 20 - rely on Microfluidizer® processors to achieve optimized nanosuspensions, nanoemulsions, liposomes, nanoencapsulation and cell disruption with highly repeatable results.

The M-110EH-30 is on display at Microfluidics exhibit booth #2214. For more capabilities and specifications, review the full press release.

In addition, visitors to the Microfluidics exhibit at INTERPHEX will have the opportunity to...


Collaborate with nanotechnology applications expert Thomai "Mimi" Panagiotou, Ph.D., Chief Technology Officer, on formulation-specific processing challenges and requirements
See the extremely popular M-110P "plug and play" benchtop processor


http://www.microfluidicscorp.com/index.php?option=com_content&task=view&id=199&Itemid=0

[cfoofme]

UP .21-WHO HAD THE FAT FINGER ?

[cfoofme]

Microfluidics and HORIBA Instruments, Inc. Announce the Formalization of Their Partnership
Tuesday January 06, 2009 09:03:01 EST
NEWTON, Mass., Jan 06, 2009 (BUSINESS WIRE) --
Microfluidics, a wholly owned subsidiary of Microfluidics International Corporation (OTCBB:MFLU) and HORIBA Instruments, Inc. are pleased to announce that their long standing partnership has been formalized. Previously, the two companies have shared marketing efforts, such as seminars and joint customer presentations. From this point forward, these efforts also will include shared exhibit booths at trade shows and exhibitions, and joint advertising and lead generation.

The two companies will also join forces in their research and development. This will include development of new products as well as enhancements for existing products for the pharmaceutical, biotechnology, food, chemical, coatings and lubricant industries. Not only will the companies collaborate on technical expertise, but they also will share laboratory facilities, office space and other tangible resources.

"The relationship between Microfluidics and HORIBA has always been mutually advantageous, but our customers will be the true beneficiaries of this new partnership," said Dr. Michael C. Pohl, HORIBA's Vice President of Scientific Instruments. "They will receive the combined expertise of both companies through a single contact and we are excited about the synergy these efforts will generate."

This new partnership is a natural development given the complimentary nature of the companies' operations. Microfluidics is a producer and distributor of proprietary high pressure and high performance materials processing equipment that reduces particle size through deagglomeration, dispersion and processing of micro-emulsions. HORIBA is a world leader in producing and distributing proprietary particle size measurement and analysis equipment. Many laboratories of their joint customers already have a Microfluidizer(R) processor sitting next to a HORIBA particle size

analyzer, but as a result of this partnership that equipment is now standard in all HORIBA and Microfluidics laboratories as well.

"HORIBA and Microfluidics have jointly served many customers over the years," noted William Kober, Microfluidics' Vice President of Sales for the Americas. "This formalized and broader partnership enables the two companies to more fully meet our customers' needs and by doing so accelerate our own companies' growth."

For more information, contact Dr. Michael C. Pohl, Vice President, Scientific Marketing, HORIBA Instruments, Inc., 17671 Armstrong Avenue, Irvine CA 92614, 800.446.7422 or 949.250.4811, [e-mail], or William Kober, Vice President of Sales for the Americas, Microfluidics, 30 Ossipee Road, Newton, MA 02464, 800.370.5452 or 617.969.5452, [e-mail].

Continued

[Aiming4]

Thanks Stockbuilder, do you have an opinion on this financing and/or the pps prospects for MFLU?

Convertible always causes a chill when you first hear it, but at the pps levels required to convert, those prices would be a very nice gain from the current share price.